Mestag Therapeutics to Present Novel LTBR Agonist MST-0312 Data at Cancer Immunotherapy Symposium
核心洞察
Mestag Therapeutics (搜索) will present preclinical data on MST-0312 (搜索), a first-in-class FAP (搜索)-targeted LTBR (搜索) agonist bispecific antibody, at the Cancer (搜索) Immunotherapy Keystone Symposia in Quebec City.
MST-0312 (搜索) is designed to induce tertiary lymphoid structures and high endothelial venules in solid tumors (搜索), which clinical evidence correlates with improved treatment response and patient survival.
Preclinical studies demonstrate that MST-0312 (搜索) monotherapy produces strong, dose-dependent anti-tumor responses, including in low-antigen tumors typically resistant to immunotherapy.
Mestag Therapeutics (搜索), a Cambridge-based biotech company specializing in fibroblast immunology, announced it will present preclinical data on its novel cancer (搜索) immunotherapy MST-0312 (搜索) at the Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations Keystone Symposia taking place March 15-18, 2026, in Québec City, Canada.
Novel Mechanism Targets Tumor Microenvironment
MST-0312 (搜索) represents a first-in-class targeted lymphotoxin beta receptor (LTBR (搜索)) agonist bispecific antibody designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors (搜索). The poster, titled "MST-0312: FAP (搜索)-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors," will be presented on March 16, 2026, during Poster Session 1.
A remarkable body of clinical evidence correlates the presence of TLS and HEV in tumors with improved response to treatment and patient survival outcomes. The formation of TLS and HEV is believed to drive improved access of lymphocytes into tumor tissue and facilitate local education and activation to tumor antigens. LTBR (搜索) serves as the key pathway driving TLS/HEV formation.
Promising Preclinical Results
Preclinical studies demonstrate that MST-0312 (搜索) monotherapy induces strong, dose-dependent anti-tumor responses, including in low-antigen tumors that are typically resistant to immunotherapy. This breakthrough suggests the therapy could address a significant unmet medical need in oncology, particularly for patients with tumors that do not respond well to current immunotherapies.
Clinical Development Timeline
MST-0312 (搜索) is planned to enter clinical development in 2026 with the initiation of the Phase 1 STARLYS trial, which is being advised by leading cancer (搜索) experts. This milestone represents a critical step in translating the promising preclinical findings into human studies.
Company Pipeline and Partnerships
Mestag's pipeline extends beyond MST-0312 (搜索) to include the M402 program, an agonist antibody targeting a stromal inhibitory receptor designed to dampen the activation of specific immune cell subsets in inflammatory disease (搜索), along with earlier-stage discovery programs.
The company has established strategic partnerships with major pharmaceutical companies. In 2024, Mestag entered into a license and research collaboration with MSD (Merck & Co. (搜索), Inc.) to identify novel targets for inflammatory diseases. Additionally, the company licensed a novel target to Johnson & Johnson under a 2021 target discovery, option and license agreement with Janssen Biotech (搜索), Inc.
Mestag utilizes its specialist fibroblast-immune RAFT Platform to identify novel targets for future therapies. The company was founded by SV Health Investors and is supported by leading life science investors including Johnson & Johnson Innovation - JJDC, Inc., Forbion, GV (Google Ventures), and Northpond Ventures.